Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

4 results about "Arterial Vasodilation" patented technology

Vasodilation directly affects the relationship between mean arterial pressure, cardiac output, and total peripheral resistance (TPR). Vasodilation occurs in the time phase of cardiac systole, whereas vasoconstriction follows in the opposite time phase of cardiac diastole.

Carotid artery vasodilatation device

PCT designated stageWO2024258387A1Magnetotherapy using coils/electromagnetsArterial VasodilationArterial occlusion
The invention to the creation of a carotid artery vasodilatation device that can be used both at home or in the emergency room in addition to drug treatment in cases such as occlusion of the carotid artery in the neck area, increases nitric oxide production mediated by endothelial nitric oxide synthase in the intact endothelial layer of the carotid artery, which will be on the inner surface of the neck collar, can be applied for certain periods of time for each patient, with intermittent or continuous operation function selections by means of its adjustable power circuits, affects only the lesion area without affecting the patient's peripheral blood vessels, can be used in cases where possible use of nitrates is contraindicated, prevents the decrease in blood flow that may occur in the brain tissue secondary to constriction in the neck veins, can be kept in the application area for a long time by means of the flexible structure of the applicator neck collar (9), and comprises pulsed magnetic field (PMF).
Owner:SÜLEYMAN DEMİREL ÜNİVERSİTESİ İDARİ VE MALİ İŞLER DAİRE BAŞKANLIĞI GENEL SEKRETERLİK

Application of 4-chloro-3-ethylphenol in the preparation of drugs for preventing or treating ulcerative colitis and sepsis

The present invention discloses the use of 4-chloro-3-ethylphenol in the preparation of drugs for preventing or treating ulcerative colitis and sepsis, and relates to the field of biomedical technology. It is experimentally confirmed in the present invention that the ryanodine receptor (RyRs) agonist 4-chloro-3-ethylphenol has significant effects in preventing or treating ulcerative colitis and sepsis, and 4-chloro-3-ethylphenol is a clinically potential drug for the preparation of drugs for preventing or treating ulcerative colitis and sepsis; meanwhile, using 4-chloro-3-ethylphenol as a reliable tool can clearly distinguish the two components of store-operated calcium channels (SOCE), that is, inducing ER / Ca<supgt;2+< / supgt; release through RyR, but blocking the entry of Ca<supgt;2+< / supgt; through SOC in vascular endothelial cells, having a dual effect; further experiments confirm that pure endothelial cell RyR / ER / Ca<supgt;2+< / supgt> release is a unique pathway for regulating EDH-mediated arterial vasodilation in a healthy state and has an anti-inflammatory effect on ulcerative colitis and sepsis.
Owner:QINGDAO UNIV

Use of acacetin or 6-hydroxyflavone in the preparation of anti-angina pectoris drugs

PendingCN122097336AOrganic active ingredientsCardiovascular disorderReflex tachycardiaAcacetin
The application belongs to the technical field of medicine, and particularly relates to application of acacetin or 6-hydroxyflavone in preparation of anti-angina pectoris drugs, and aims to solve the problems of adverse reactions such as blood pressure drop, reflex tachycardia and the like caused by non-selective vasodilation of existing anti-angina pectoris drugs, wherein the drug improves myocardial blood supply by selectively dilating coronary vessels of the heart, wherein acacetin dilates coronary vessels of the heart by inhibiting cardiac coronary vessel myosin light chain kinase and activating myosin light chain phosphatase, and 6-hydroxyflavone dilates coronary vessels of the heart by inhibiting protein kinase C and enhancing myosin light chain phosphatase activity; and the acacetin or 6-hydroxyflavone significantly reduces the symptoms of myocardial ischemia of rats caused by isopropyl adrenaline, improves characteristic ECG abnormal changes of angina pectoris, does not affect heart rate and systemic blood pressure, and is safer, thereby providing a potential drug selection for anti-angina pectoris treatment.
Owner:NANJING ANMAOHUA PHARM CO LTD

Application of 4-chloro-3-ethyl phenol in preparation of medicine for preventing or treating ulcerative colitis and septicopyemia

The invention discloses application of 4-chloro-3-ethyl phenol in preparation of a medicine for preventing or treating ulcerative colitis and septicopyemia, and relates to the technical field of biological medicine. Experiments prove that the raney receptor (RyRs) agonist 4-chloro-3-ethyl phenol has a remarkable effect on preventing or treating ulcerative colitis and septicopyemia, and the 4-chloro-3-ethyl phenol is a clinical potential medicine for preventing or treating ulcerative colitis and septicopyemia; meanwhile, 4-chloro-3-ethylphenol is used as a reliable tool, two components of a calcium channel (SOCE) controlled by a calcium pool can be clearly distinguished, that is, ER / Ca < 2 + > release is induced through RyR, but Ca < 2 + > passing through SOC in vascular endothelial cells is blocked from entering, and dual effects are achieved; further experiments prove that pure endothelial cell RyR / ER / Ca < 2 + > release is a unique way for regulating EDH-mediated artery vasodilation in a healthy state, and has an anti-inflammatory effect on ulcerative colitis and septicopyemia.
Owner:QINGDAO UNIV